(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 12.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Adma Biologics's revenue in 2026 is $519,153,000.On average, 5 Wall Street analysts forecast ADMA's revenue for 2026 to be $121,358,787,871, with the lowest ADMA revenue forecast at $115,373,156,456, and the highest ADMA revenue forecast at $126,496,935,520. On average, 5 Wall Street analysts forecast ADMA's revenue for 2027 to be $142,461,577,352, with the lowest ADMA revenue forecast at $130,434,850,925, and the highest ADMA revenue forecast at $156,473,900,562.
In 2028, ADMA is forecast to generate $164,986,453,468 in revenue, with the lowest revenue forecast at $144,167,637,604 and the highest revenue forecast at $190,450,900,237.